Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Drug Discovery,Molecular Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12272-022-01385-3.pdf
Reference131 articles.
1. Andersson E, Arvidsson Y, Sward C, Hofving T, Wangberg B, Kristiansson E, Nilsson O (2016) Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets. Mod Pathol 29:616–629. https://doi.org/10.1038/modpathol.2016.48
2. Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A (2016) Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget 7:80543–80553. https://doi.org/10.18632/oncotarget
3. Awad M (2020) A study of alectinib in RET-rearranged non-small cell lung cancer or RET-mutated thyroid cancer. https://clinicaltrials.gov/ct2/show/NCT03131206?term=NCT03131206&draw=2&rank=1. Accessed 16 Mar 2020
4. Baglivo S, Ludovini V, Moretti R, Bellezza G, Sidoni A, Roila F, Metro G (2020) RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. Oncol Ther 8:333–339. https://doi.org/10.1007/s40487-020-00116-2
5. Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32:337–350. https://doi.org/10.1016/j.annonc.2020.11.021
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib;Critical Reviews in Oncology/Hematology;2024-02
2. Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement;Cancer Research and Treatment;2023-10-15
3. First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis;Translational Lung Cancer Research;2023-09
4. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical;Molecules;2023-06-09
5. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer;Journal of Translational Medicine;2022-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3